Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $21.10 Average Price Target from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given a consensus recommendation of “Buy” by the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $21.10.

TRVI has been the topic of several research analyst reports. Leerink Partners raised their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Oppenheimer raised their price objective on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Stifel Nicolaus boosted their price objective on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, December 19th. D. Boral Capital reiterated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC raised its holdings in shares of Trevi Therapeutics by 15.3% in the fourth quarter. ProShare Advisors LLC now owns 22,269 shares of the company’s stock valued at $279,000 after purchasing an additional 2,947 shares during the last quarter. Nan Fung Trinity HK Ltd. boosted its holdings in Trevi Therapeutics by 924.2% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock worth $11,486,000 after purchasing an additional 827,875 shares during the last quarter. F m Investments LLC bought a new position in Trevi Therapeutics in the fourth quarter valued at $3,023,000. Oppenheimer & Co. Inc. increased its stake in Trevi Therapeutics by 2.1% in the 4th quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company’s stock valued at $1,261,000 after buying an additional 2,030 shares during the last quarter. Finally, Comerica Bank lifted its position in Trevi Therapeutics by 19,481.8% during the 4th quarter. Comerica Bank now owns 83,027 shares of the company’s stock worth $1,039,000 after buying an additional 82,603 shares in the last quarter. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Trading Up 4.8%

TRVI stock opened at $11.46 on Friday. Trevi Therapeutics has a 1-year low of $3.77 and a 1-year high of $14.39. The firm has a market cap of $1.47 billion, a PE ratio of -30.97 and a beta of 0.94. The business’s 50-day moving average price is $11.90 and its two-hundred day moving average price is $10.18.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. On average, analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.